Bioequivalence study followed by model‐informed dose optimization of a powder for oral suspension of 6‐mercaptopurine
Pediatric Blood & Cancer · 2024
DOI: 10.1002/pbc.30813 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, 2024. Verfasst von Bhavatharini Arun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra,…. Hauptthemen laut MEDLINE: Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Indian Council of Medical Research (ICMR).
Abstract (Originalsprache)
Background
6‐Mercaptopurine (6MP) is the mainstay chemotherapy for acute lymphoblastic leukemia (ALL) and is conventionally available as 50 mg tablets. A new 6MP powder for oral suspension (PFOS 10 mg/mL) was developed recently by IDRS Labs, India, intended for pediatric use. A comparative pharmacokinetics of PFOS with T. mercaptopurine was conducted to determine the dose equivalence.
Methods
An open‐label, randomized, two‐treatment, two‐period, two‐sequence, single oral dose, crossover, bioequivalence study was conducted on 51 healthy adult subjects. Post hoc, a population pharmacokinetic (PopPK) model was developed using the healthy volunteer data to perform simulations with various PFOS doses and select a bioequivalent dose. Further, to confirm the safety of PFOS in pediatrics, a simulation of 6MP and 6‐thioguanine exposures was performed by incorporating the formulation‐specific parameters derived from the healthy volunteer study into the PopPK model in childhood ALL available in literature.
Results
The 6MP PFOS had 47% higher oral bioavailability compared to the reference product. Simulations using a two‐compartmental PopPK model with dissolution and transit compartments showed that 40 mg of PFOS was found to be equivalent to 50 mg tablets. The simulated 6‐thioguanine nucleotide concentrations in children using the dose adjusted for PFOS were between 114 and 703.6 pmol/8 × 10 8 RBC, which was within the range reported in pediatric ALL studies.
Conclusion
6MP PFOS 10 mg/mL should be administered at a 20% lower dose than the tablet to achieve comparable exposure. 6MP PFOS addresses an unmet medical need for a liquid formulation of 6MP in the Indian subcontinent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, Maharashtra, India.
- IDRS Labs Pvt Ltd., Bengaluru, Karnataka, India.
- Pumas AI, Inc., Centreville, Virginia, USA.
- Department of Paediatric Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India.
- Homi Bhabha National Institute, Anushakthinagar, Mumbai, Maharashtra, India.
ORCID-Profile: Vikram Gota
Förderung
- Indian Council of Medical Research (ICMR)
Zitieren
APA
Arun, B., Joshi, M., Kakkar, A. K., Madki, S., Ivaturi, V., Chinnaswamy, G., Banavali, S., & Gota, V. (2024). Bioequivalence study followed by model‐informed dose optimization of a powder for oral suspension of 6‐mercaptopurine. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30813
Vancouver
Arun B, Joshi M, Kakkar AK, Madki S, Ivaturi V, Chinnaswamy G, et al. Bioequivalence study followed by model‐informed dose optimization of a powder for oral suspension of 6‐mercaptopurine. Pediatric Blood & Cancer. 2024. doi:10.1002/pbc.30813
BibTeX
@article{Arun2024,
author = {Arun, Bhavatharini and Joshi, Mahendra and Kakkar, Archana Khosa and Madki, Shivkumar and Ivaturi, Vijay and Chinnaswamy, Girish and Banavali, Shripad and Gota, Vikram},
title = {Bioequivalence study followed by model‐informed dose optimization of a powder for oral suspension of 6‐mercaptopurine},
journal = {Pediatric Blood & Cancer},
year = {2024},
doi = {10.1002/pbc.30813}
}
EUVIMED